MicroRNAs in vascular tissue engineering and post-ischemic neovascularization

Massimo Caputo, Jaimy Saif, Cha Rajakaruna, Marcus Brooks, Gianni D Angelini, Costanza Emanueli

Research output: Contribution to journalReview article

Abstract

Increasing numbers of paediatric patients with congenital heart defects are surviving to adulthood, albeit with continuing clinical needs. Hence, there is still scope for revolutionary new strategies to correct vascular anatomical defects. Adult patients are also surviving longer with the adverse consequences of ischemic vascular disease, especially after acute coronary syndromes brought on by plaque erosion and rupture. Vascular tissue engineering and therapeutic angiogenesis provide new hope for these patients. Both approaches have shown promise in laboratory studies, but have not yet been able to deliver clear evidence of clinical success. More research into biomaterials, molecular medicine and cell and molecular therapies is necessary. This review article focuses on the new opportunities offered by targeting microRNAs for the improved production and greater empowerment of vascular cells for use in vascular tissue engineering or for increasing blood perfusion of ischemic tissues by amplifying the resident microvascular network.

Original languageEnglish
Pages (from-to)78-91
Number of pages14
JournalAdvanced Drug Delivery Reviews
Volume88
DOIs
Publication statusPublished - 1 Jul 2015

Fingerprint

Tissue Engineering
MicroRNAs
Blood Vessels
Hope
Molecular Medicine
Congenital Heart Defects
Biocompatible Materials
Acute Coronary Syndrome
Cell- and Tissue-Based Therapy
Microvessels
Vascular Diseases
Rupture
Perfusion
Pediatrics
Research
Therapeutics

Bibliographical note

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords

  • Aneurysm/pathology
  • Blood Vessels/metabolism
  • Endothelial Cells/metabolism
  • Extracellular Matrix/metabolism
  • Heart Defects, Congenital/pathology
  • Humans
  • Ischemia/pathology
  • MicroRNAs/metabolism
  • Muscle, Smooth, Vascular/metabolism
  • Neovascularization, Pathologic/metabolism
  • Pericytes/metabolism
  • Stem Cells/metabolism
  • Tissue Engineering/methods

Cite this

Caputo, Massimo ; Saif, Jaimy ; Rajakaruna, Cha ; Brooks, Marcus ; Angelini, Gianni D ; Emanueli, Costanza. / MicroRNAs in vascular tissue engineering and post-ischemic neovascularization. In: Advanced Drug Delivery Reviews. 2015 ; Vol. 88. pp. 78-91.
@article{b8d201b6e08546c68d36c7adaf00ea3f,
title = "MicroRNAs in vascular tissue engineering and post-ischemic neovascularization",
abstract = "Increasing numbers of paediatric patients with congenital heart defects are surviving to adulthood, albeit with continuing clinical needs. Hence, there is still scope for revolutionary new strategies to correct vascular anatomical defects. Adult patients are also surviving longer with the adverse consequences of ischemic vascular disease, especially after acute coronary syndromes brought on by plaque erosion and rupture. Vascular tissue engineering and therapeutic angiogenesis provide new hope for these patients. Both approaches have shown promise in laboratory studies, but have not yet been able to deliver clear evidence of clinical success. More research into biomaterials, molecular medicine and cell and molecular therapies is necessary. This review article focuses on the new opportunities offered by targeting microRNAs for the improved production and greater empowerment of vascular cells for use in vascular tissue engineering or for increasing blood perfusion of ischemic tissues by amplifying the resident microvascular network.",
keywords = "Aneurysm/pathology, Blood Vessels/metabolism, Endothelial Cells/metabolism, Extracellular Matrix/metabolism, Heart Defects, Congenital/pathology, Humans, Ischemia/pathology, MicroRNAs/metabolism, Muscle, Smooth, Vascular/metabolism, Neovascularization, Pathologic/metabolism, Pericytes/metabolism, Stem Cells/metabolism, Tissue Engineering/methods",
author = "Massimo Caputo and Jaimy Saif and Cha Rajakaruna and Marcus Brooks and Angelini, {Gianni D} and Costanza Emanueli",
note = "{\circledC} 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/)",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.addr.2015.05.003",
language = "English",
volume = "88",
pages = "78--91",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

MicroRNAs in vascular tissue engineering and post-ischemic neovascularization. / Caputo, Massimo; Saif, Jaimy; Rajakaruna, Cha; Brooks, Marcus; Angelini, Gianni D; Emanueli, Costanza.

In: Advanced Drug Delivery Reviews, Vol. 88, 01.07.2015, p. 78-91.

Research output: Contribution to journalReview article

TY - JOUR

T1 - MicroRNAs in vascular tissue engineering and post-ischemic neovascularization

AU - Caputo, Massimo

AU - Saif, Jaimy

AU - Rajakaruna, Cha

AU - Brooks, Marcus

AU - Angelini, Gianni D

AU - Emanueli, Costanza

N1 - © 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/)

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Increasing numbers of paediatric patients with congenital heart defects are surviving to adulthood, albeit with continuing clinical needs. Hence, there is still scope for revolutionary new strategies to correct vascular anatomical defects. Adult patients are also surviving longer with the adverse consequences of ischemic vascular disease, especially after acute coronary syndromes brought on by plaque erosion and rupture. Vascular tissue engineering and therapeutic angiogenesis provide new hope for these patients. Both approaches have shown promise in laboratory studies, but have not yet been able to deliver clear evidence of clinical success. More research into biomaterials, molecular medicine and cell and molecular therapies is necessary. This review article focuses on the new opportunities offered by targeting microRNAs for the improved production and greater empowerment of vascular cells for use in vascular tissue engineering or for increasing blood perfusion of ischemic tissues by amplifying the resident microvascular network.

AB - Increasing numbers of paediatric patients with congenital heart defects are surviving to adulthood, albeit with continuing clinical needs. Hence, there is still scope for revolutionary new strategies to correct vascular anatomical defects. Adult patients are also surviving longer with the adverse consequences of ischemic vascular disease, especially after acute coronary syndromes brought on by plaque erosion and rupture. Vascular tissue engineering and therapeutic angiogenesis provide new hope for these patients. Both approaches have shown promise in laboratory studies, but have not yet been able to deliver clear evidence of clinical success. More research into biomaterials, molecular medicine and cell and molecular therapies is necessary. This review article focuses on the new opportunities offered by targeting microRNAs for the improved production and greater empowerment of vascular cells for use in vascular tissue engineering or for increasing blood perfusion of ischemic tissues by amplifying the resident microvascular network.

KW - Aneurysm/pathology

KW - Blood Vessels/metabolism

KW - Endothelial Cells/metabolism

KW - Extracellular Matrix/metabolism

KW - Heart Defects, Congenital/pathology

KW - Humans

KW - Ischemia/pathology

KW - MicroRNAs/metabolism

KW - Muscle, Smooth, Vascular/metabolism

KW - Neovascularization, Pathologic/metabolism

KW - Pericytes/metabolism

KW - Stem Cells/metabolism

KW - Tissue Engineering/methods

UR - https://www.sciencedirect.com/science/article/pii/S0169409X15000964?via%3Dihub

U2 - 10.1016/j.addr.2015.05.003

DO - 10.1016/j.addr.2015.05.003

M3 - Review article

C2 - 25980937

VL - 88

SP - 78

EP - 91

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -